IXICO, a company specializing in precision analytics for neuroscience, has been awarded a £500,000 contract to support a Phase II clinical trial targeting Huntington's disease. This contract underscores IXICO's growing role in providing critical data analytics and imaging services for neurodegenerative disease research.
The contract will see IXICO deploying its Assessa® and TrialTracker® platforms. Assessa® is designed to provide advanced imaging analytics, extracting quantitative data from brain scans to assess disease progression and treatment response. TrialTracker® offers a comprehensive data management solution, ensuring efficient and secure handling of clinical trial data.
"This contract further validates our strategy to be the leading imaging and data analytics partner for pharmaceutical companies developing novel therapies for neurodegenerative diseases," stated a company representative. The collaboration aims to enhance the precision and efficiency of the clinical trial, potentially accelerating the development of new treatments for Huntington's disease.
Huntington's disease is a progressive neurodegenerative disorder affecting motor control, cognition, and psychiatric health. There is currently no cure for Huntington's disease, and treatments are primarily focused on managing symptoms. This Phase II trial represents an important step in evaluating a potential new therapy, and IXICO's involvement will provide valuable insights into the drug's efficacy and impact on brain structure.
The project is set to commence immediately and is expected to positively impact IXICO's revenue stream. By leveraging its expertise in neuroimaging and data analytics, IXICO is contributing to the advancement of Huntington's disease research and the broader field of neuroscience.
